Editorial
Standards

This page explains how we research and write the content on GlobalGLP1: what sources we trust, how we handle medical claims, when we update articles, and what conflicts of interest we disclose. If we cite a number or make a claim, we want you to be able to trace it.

Editorial policy last reviewed: March 2026.

When we write about medications, weight loss outcomes, side effects, dosing, or insurance coverage, we cite sources in this order of priority:

1. FDA prescribing information. The official drug label is the primary source for indications, dosing, contraindications, warnings, and approved use cases. Labels are linked directly from medication pages where applicable.

2. Peer-reviewed clinical trials. We cite published trial data from journals like the New England Journal of Medicine (NEJM), JAMA, The Lancet, and Diabetes Care for efficacy, safety, and outcome claims. We name the trial (STEP, SURMOUNT, SCALE, SUSTAIN, etc.) and link the publication where possible.

3. Manufacturer medical information. Novo Nordisk and Eli Lilly publish patient-facing dosing schedules, savings programs, and prescribing data. We use this for pricing and program details, clearly attributed.

4. Federal health agencies. CMS (Medicare/Medicaid), CDC, and NIH for coverage policy, public health statistics, and clinical guidance.

5. Reputable health journalism. STAT, Reuters Health, AP, NPR Health, and major medical journals' news desks, used as secondary references and never as the sole source for a medical claim.

Content on GlobalGLP1 is produced by an in-house editorial team led by our founder, with research and writing experience in digital health publishing. No member of our editorial team is a licensed physician or other medical professional. We do not provide medical advice, diagnoses, or treatment recommendations. Everything we publish is informational, sourced from the primary references above, and should be discussed with a qualified clinician before acting on it.

Every medication page, insurance guide, and blog post is reviewed against its primary sources before publication. Articles are updated when the FDA approves a new indication, when a major trial publishes new data, when a manufacturer changes pricing or savings programs, or when a reader flags an error we verify.

Medication pages (Wegovy, Ozempic, Mounjaro, Zepbound, semaglutide, tirzepatide, liraglutide) are reviewed at least quarterly and immediately when the FDA issues new approvals, label changes, safety communications, or when a major trial publishes outcome data.

Insurance pages (Aetna, BCBS, Cigna, UHC, Medicare, Medicaid, state-by-state coverage) are reviewed at least quarterly and immediately when CMS publishes new coverage policy or when a major payer announces a formulary change.

Clinic listings are refreshed on a rolling basis from Google Business data, the clinic's own website, and owner-submitted updates. Each listing displays the date of last review.

Blog posts and guides are reviewed annually as a baseline, and immediately when reader feedback or new published research warrants a substantive update. Articles with substantive corrections carry a dated correction note at the bottom.

We use software to gather public data at scale (Google Business profiles, clinic websites, regulatory databases) and to draft initial content outlines. Every published article and every medical claim is reviewed against primary sources by a human editor before publication. We do not publish AI-generated medical content without source review and editorial sign-off.

We do not use AI to generate fake reviews, fake credentials, fake testimonials, or fabricated medical statistics. We do not publish content under fictional author names. If a piece is written by our editorial team, the byline reads "GlobalGLP1 Editorial Team" because that is what is true.

How we make money: Optional premium listings for clinics ($99 per month) that give them enhanced visibility in the default sort order on city, state, and search results pages. Premium listings are always labeled "Sponsored."

Editorial content is independent of advertising. Premium status does not affect medication page content, insurance page content, blog post coverage, ratings, patient reviews, or ranking on editorial pages like "Top Rated," "Best Telehealth," "Best Semaglutide," and "Best Tirzepatide." Editorial ranking pages explicitly exclude paid placement boosts. See our full ranking methodology.

What we do not accept: Payment for editorial coverage. Affiliate commissions on clinic bookings or medication referrals. Payment from pharmaceutical manufacturers. Payment for blog posts, sponsored articles, or guest content. We do not sell patient contact information or user data.

Ownership: GlobalGLP1 is independently owned and operated. We are not affiliated with any pharmaceutical manufacturer, telehealth platform, or clinic network. We are based in Miami, Florida.

We make mistakes. When you find one, our corrections policy explains exactly how to report it and how fast you should expect a response (2 business days for factual errors, 5 business days for listing details).

Substantive corrections on blog posts and guides are dated and noted at the bottom of the article. We do not silently rewrite published content to hide errors.